INS and diabetes mellitus: So far, reviews investigating insulin pump therapy showed mixed results regarding the health-related quality of life (HRQOL) in paediatric diabetes patients.[13, 16, 17] According to recent publications,[15, 18–20] there is still a lack of adequately powered studies to underpin the advantages of CSII regarding QoL improvement for children diagnosed with DM and to potentially balance the higher treatment cost attached to it.[8] Thus, insulin pumps are–forty years after they were first introduced to the market–still not part of first-line recommendations in most countries around the world.